Showing results (301-310 of 340) with videos related to

Sort By:
Pageof 34
European Journal of Preventive Cardiology|August 1, 2015
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markersBauke Schievink, Dick de Zeeuw, Paul A Smink, et al.
The New England Journal of Medicine|September 17, 2010
Erythropoietic response and outcomes in kidney disease and type 2 diabetesScott D Solomon, Hajime Uno, Eldrin F Lewis, et al.
JACC. Heart Failure|June 30, 2022
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart FailureJ David Smeijer, Jeroen Koomen, Donald E Kohan, et al.
Clinical Pharmacology and Therapeutics|July 27, 2022
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney DiseaseJ David Smeijer, Jeroen V Koomen, Donald E Kohan, et al.
American Heart Journal|December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trialAshish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International|December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practiceMegumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 11, 2017
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKDDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
Lancet (London, England)|April 19, 2019
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 2, 2019
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines AgencyAndrew S Levey, Ron T Gansevoort, Josef Coresh, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 31, 2013
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trialHiddo J Lambers Heerspink, Glenn M Chertow, Tadao Akizawa, et al.
Pageof 34